Adverse Events of Adjuvant Mitotane Treatment for Adrenocortical Carcinoma
Careful monitoring and timely management are essential for ensuring mitotane treatment adherence and maximizing its benefits.
Authors
- Karin Zibar (ORCID: https://orcid.org/0000-0002-1694-6891)
- Ivana Dora Vodanović (ORCID: https://orcid.org/0000-0002-5380-4411)
- Anja Barač Nekić (ORCID: https://orcid.org/0000-0003-2672-8529)
- Tina Dušek (ORCID: https://orcid.org/0000-0002-1266-3501)
- Darko Kaštelan (ORCID: https://orcid.org/0000-0003-3034-5598)
- Lana Šambula
Institutions
- University Hospital Centre Zagreb (HR)
- University of Zagreb (HR)
Publication Details
- Journal
- Endocrine Research
- Published
- 2024-09-15
- DOI
- https://doi.org/10.1080/07435800.2024.2402311
- Citations
- 3
- Primary Topic
- Adrenal and Paraganglionic Tumors
- Type
- article
- Field-Weighted Citation Impact
- 1.72